A Possible Role for Pioglitazone in the Management of Depressive Symptoms in Metabolic Syndrome Patients (EPICAMP Study): A Double Blind, Randomized Clinical Trial

Table 3

New onset or aggravated symptoms recorded during the follow-up period.

Symptom number of cases (%)	Placebo	Pioglitazone	value
Peripheral edema	6 (11.8)	8 (15.1)	.556
Dizziness	0 (0)	4 (7.5)	.116
Headache	0 (0)	3 (5.7)	.241
Tiredness	0 (0)	2 (3.8)	.494
Cardiac arrhythmia	0 (0)	2 (3.8)	.494
Dyspnea on exertion	2 (3.9)	0 (0)	.494
Nausea	0 (0)	1 (1.9)	.999